Blood-based protein biomarker panel for the detection of colorectal cancer

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Fung, Kim Y C ^a   Tabor, Bruce ^a   Buckley, Michael J ^a   Priebe, Ilka K ^a   Purins, Leanne ^a   Pompeia, Celine ^a   Brierley, Gemma V ^a   Lockett, Trevor ^a   Gibbs, Peter ^b   Tie, Jeanne ^b   McMurrick, Paul ^c   Moore, James ^d   Ruszkiewicz, Andrew ^e   Nice, Edouard ^f   Adams, Timothy E ^a   Burgess, Antony ^g,h   Cosgrove, Leah J ^a  

^a CSIRO   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c CABRINI HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e SA Pathology   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DICKKOPF 3 PROTEIN; GLYCOPROTEIN; PYRUVATE KINASE; PYRUVATE KINASE M2; SOMATOMEDIN BINDING PROTEIN 2; TUMOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; DKK3 PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL PEPTIDE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER SCREENING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; RELIABILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; EVALUATION STUDY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; THYROID HORMONES;

EID: 84925655307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120425     Document Type: Article

References (53)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127: 2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269
2. World Cancer Research Fund and American Institute for Cancer Research 2007. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767. PMID: 2188735
4. Moran A, Ortega P, de Juan C, Fernandez-Marcelo T, Frias C, Sanchez-Pernaute A, et al. Differential colorectal carcinogenesis: Molecular basis and clinical relevance. World J Gastrointest Oncol. 2010; 2: 151-158. doi: 10.4251/wjgo.v2.i3.151 PMID: 21160823
5. Power DG, Gloglowski E, Lipkin SM. Clinical genetics of hereditary colorectal cancer. Hematol Oncol Clin North Am. 2010; 24: 837-859. doi: 10.1016/j.hoc.2010.06.006 PMID: 20816577
6. Australian Institute of Health and Welfare 2012. National Bowel Cancer Screening Program monitoring report: phase 2, July 2008-June 2011. CANCER SERIES NO 65 CAN 61. Canberra: AIHW.
7. Burt RW, Cannon JA, David DS, Early DS, Ford JM, Giardiello FM, et al. Colorectal cancer screening. J Natl Compr Canc Netw. 2013; 11: 1538-1575. PMID: 24335688
8. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2011; 128: 3-11. doi: 10.1002/ijc.25654 PMID: 20824704
9. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol. 2013; 10: 130-142. doi: 10.1038/nrclinonc.2013.12 PMID: 23381005
10. He J, Efron JE. Screening for colorectal cancer. Adv Surg. 2011; 45: 31-44. PMID: 21954677
11. Moawad FJ, Maydonovitch CL, Cullen PA, Barlow DS, Jenson DW, Cash BD. CT colonography may improve colorectal cancer screening compliance. AJR Am J Roentgenol. 2010; 195: 1118-1123. doi: 10.2214/AJR.10.4921 PMID: 20966316
12. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, Nicolas D, Moreno SG, Jimenez A, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol. 2010; 45: 703-712. doi: 10.1007/s00535-010-0214-8 PMID: 20157748
13. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol. 2010; 24: 479-492. doi: 10.1016/j.bpg.2010.03.009 PMID: 20833351
14. Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis. 2012; 27: 1657-1664. doi: 10.1007/s00384-012-1518-3 PMID: 22696204
15. Bunger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, et al. Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen. 2011; 16: 1018-1026. doi: 10.1177/1087057111414894 PMID: 21807963
16. de Wit M, Kant H, Piersma SR, Pham TV, Mongera S, van Berkel MP, et al. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. J Proteomics. 2014; 99C: 26-39.
17. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013; 258: 400-408. doi: 10.1097/SLA.0b013e3182a15bcc PMID: 24022433
18. Marshall KW, Mohr S, Khettabi FE, Nossova N, Chao S, Bao W, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010; 126: 1177-1186. doi: 10.1002/ijc.24910 PMID: 19795455
19. Pengjun Z, Xinyu W, Feng G, Xinxin D, Yulan L, Juan L, et al. Multiplexed cytokine profiling of serum for detection of colorectal cancer. Future Oncol. 2013; 9: 1017-1027. doi: 10.2217/fon.13.71 PMID: 23837764
20. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009; 55: 1337-1346. doi: 10.1373/clinchem.2008.115808 PMID: 19406918
21. Grutzmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008; 3: e3759. doi: 10.1371/journal.pone.0003759 PMID: 19018278
22. Toth K, Sipos F, Kalmar A, Patai AV, Wichmann B, Stoehr R, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One. 2012; 7: e46000. doi: 10.1371/journal.pone.0046000 PMID: 23049919
23. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011; 9: 133. doi: 10.1186/1741-7015-9-133 PMID: 22168215
24. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012; 142: 248-256; quiz e225-246. doi: 10.1053/j.gastro.2011.10.031 PMID: 22062357
25. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. N Engl J Med. 2014; 370: 1287-1297. doi: 10.1056/NEJMoa1311194 PMID: 24645800
26. Fung KYC, Purins L, Priebe IK, Pompeia C, Brierley GV, Tabor B, et al. Analysis of 32 Blood-Based Protein Biomarkers for their Potential to Diagnose Colorectal Cancer. J Mol Biomark Diagn. 2014: 003.
27. Edge SB, Byrd DR, Compton CC (2010) American Joint Committee on Cancer, American Cancer Society: AJCC cancer staging handbook: From the AJCC cancer staging manual. New York: Springer.
28. Brierley GV, Priebe IK, Purins L, Fung KY, Tabor B, Lockett T, et al. Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 2013; 13: 67-73. doi: 10.3233/CBM-130345 PMID: 23838134
29. Fung KY, Priebe I, Purins L, Tabor B, Brierley GV, Lockett T, et al. Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer. Cancer Biomark. 2013; 13: 75-79. doi: 10.3233/CBM-130335 PMID: 23838135
30. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12: 77. doi: 10.1186/1471-2105-12-77 PMID: 21414208
31. Diehl D, Hessel E, Oesterle D, Renner-Muller I, Elmlinger M, Langhammer M, et al. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer. 2009; 124: 2220-2225. doi: 10.1002/ijc.24193 PMID: 19142966
32. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007; 121: 368-376. PMID: 17372899
33. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010; 95: 1717-1725. doi: 10.1210/jc.2009-2668 PMID: 20157191
34. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer. 2000; 83: 1344-1350. PMID: 11044360
35. Sunderic M, Dukanovic B, Malenkovic V, Nedic O. Molecular forms of the insulin-like growth factorbinding protein-2 in patients with colorectal cancer. Exp Mol Pathol. 2013; 96: 48-53. doi: 10.1016/j.yexmp.2013.11.006 PMID: 24275430
36. Maehata T, Taniguchi H, Yamamoto H, Nosho K, Adachi Y, Miyamoto N, et al. Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer. World J Gastroenterol. 2008; 14: 2702-2714. PMID: 18461655
37. Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis. 2007; 28: 2459-2466. PMID: 17675336
38. Zitt M, Untergasser G, Amberger A, Moser P, Stadlmann S, Zitt M, et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers. 2008; 24: 101-109. PMID: 18219095
39. Demir AS, Erdenen F, Muderrisoglu C, Toros AB, Bektas H, Gelisgen R, et al. Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal canhcer. Turk J Gastroenterol. 2013; 24: 36-42. PMID: 23794342
40. Hardt PD, Ewald N. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn. 2008; 8: 579-585. doi: 10.1586/14737159.8.5.579 PMID: 18785806
41. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res. 2003; 23: 851-853. PMID: 12820312
42. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer. 2008; 99: 133-135. doi: 10.1038/sj.bjc.6604427 PMID: 18542075
43. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis. 2008; 10: 244-248. PMID: 17784868
44. Li R, Liu J, Xue H, Huang G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis. Int J Cancer. 2012; 131: 1837-1845. doi: 10.1002/ijc.27442 PMID: 22261915
45. Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, et al. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol. 2007; 19: 878-882. PMID: 17873612
46. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer. 2006; 119: 2651-2656. PMID: 16929517
47. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology. 2012; 142: 422-424. doi: 10.1053/j.gastro.2012.01.015 PMID: 22281273
48. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007; 99: 1462-1470. PMID: 17895475
49. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005; 129: 422-428. PMID: 16083699
50. Osborne JM, Wilson C, Moore V, Gregory T, Flight I, Young GP. Sample preference for colorectal cancer screening tests: Blood or stool? Open Journal of Preventative Medicine. 2012; 2: 326-331.
51. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med. 2012; 55: 87-92. doi: 10.1016/j.ypmed.2012.05.006 PMID: 22634386
52. Schroy PC 3rd, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med. 2005; 28: 208-214. PMID: 15710277
53. Hol L, de Bekker-Grob EW, van Dam L, Donkers B, Kuipers EJ, Habbema JD, et al. Preferences for colorectal cancer screening strategies: a discrete choice experiment. Br J Cancer. 2010; 102: 972-980. doi: 10.1038/sj.bjc.6605566 PMID: 20197766